

Correction to “Development of a Manufacturing Process for an HCV Protease Inhibitor Candidate Molecule”

Benjamin J. Littler,* Michael Aizenberg, Narendra B. Ambhaikar, Todd A. Blythe, Timothy T. Curran, Vadims Dvornikovs, Young C. Jung, Valdas Jurkauskas, Elaine C. Lee, Adam R. Looker, Hoa Luong, Theodore A. Martinot, David B. Miller, Bobbianna J. Neubert-Langille, Pieter A. Otten, Peter J. Rose, and Piero L. Ruggiero

Chemical Development, Vertex Pharmaceuticals Incorporated, 50 Northern Avenue, Boston, Massachusetts 02210, United States, and 11010 Torreyana Road, San Diego, California 92121, United States

Org. Process Res. Dev. **2015**, *19* (1), 270–283; 10.1021/op500210w

It has been brought to our attention that the structure for compound 7 was incorrectly drawn in Schemes 6 and 7 of our recently published manuscript “Development of a Manufacturing Process for an HCV Protease Inhibitor Candidate Molecule” (DOI: 10.1021/op500210w) as shown below in Figure 1.






Figure 1. Correction required to the structure of compound 7 in Schemes 6 and 7.

The corrected versions of Schemes 6 and 7 are shown here.

Scheme 6. Initial approach to isolate spirocycle 2 as a single diastereomer (corrected)



Scheme 7. Pilot-plant synthesis of spirocycle 2•HCl (corrected)



AUTHOR INFORMATION

Corresponding Author

*E-mail: benjamin_littler@vrtx.com.